Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Supreme Court Protects Access to Common Abortion Pill

Supreme Court preserves access to widely used abortion pill, while lawsuit plays out

STAT News1 min readAI-assisted summary
Editorial illustration for Supreme Court preserves access to widely used abortion pill, while lawsuit plays out
Editorial illustration

Summary

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system.

Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

Why it matters.

This legal decision is highly significant for patients seeking reproductive healthcare, as it protects the primary method used for abortions today. Maintaining the ability to receive this medication by mail or at a local pharmacy removes major logistical barriers for patients, especially those who might struggle to attend an in-person medical appointment.

It is important to note that this update reflects a temporary legal and regulatory status rather than new clinical trial data or scientific research. Because the Supreme Court order is an interim measure, the long-term future of mifepristone distribution relies on the final outcome of the ongoing lawsuit. Until the legal system reaches a permanent conclusion, patients and healthcare providers will be watching closely.

From the source

The story in numbers.

Quantitative clinical figures not present in text
N/A
Sample size (Not applicable to legal summary)
N/A
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read
Drug Development

New Weight-Loss Pill Shows 12.4 Percent Drop Over One Year

A new player is entering the rapidly expanding world of weight-loss treatments. Vincentage Pharma recently announced that its experimental daily pill helped patients lose an average of 12.4 percent of their body weight over a 12-month period. The drug is an oral GLP-1 agonist, which is a type of medicine that mimics a natural hormone in the body to regulate appetite and blood sugar. This approach works similarly to popular injectable treatments currently on the market but comes in a convenient pill form. Following these promising results, the biotechnology company plans to submit its treatment to Chinese regulators for approval. However, it is important to view these early numbers with caution. The initial reports lack detailed clinical trial data, meaning we do not yet know the number of patients tested, the specific phase of the research, or any safety profiles and side effects the participants might have experienced.

Fierce Biotech1 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗